Table 1. Functional analysis of significant CpGs in three cell types.
| DAVID/Panther GO Term | p-value | FDR % |
| Genes near top 100 CD4 CpGs | ||
| BP00156: Interferon-mediated immunity | 5.80E-07 | 5.90E-04 |
| BP00148: Immunity and defense | 3.80E-03 | 3.80422 |
| Genes near top 100 CD14 CpGs | ||
| BP00156: Interferon-mediated immunity | 2.20E-08 | 2.10E-05 |
| BP00148: Immunity and defense | 8.60E-08 | 8.20E-05 |
| Genes near top 100 CD19 CpGs | ||
| BP00156: Interferon-mediated immunity | 9.00E-07 | 9.20E-04 |
| BP00148: Immunity and defense | 2.20E-05 | 2.20E-02 |
| Genes near CD4 CpGs with 1E-08>P>1E-11 | ||
| BP00064: Protein phosphorylation | 4.09E-04 | 0.4938 |
| BP00281: Oncogenesis | 6.16E-04 | 0.7434 |
| BP00152: B-cell and antibody-mediated immunity | 0.0014738 | 1.7689 |
| BP00063: Protein modification | 0.0017254 | 2.0679 |
| BP00253: Induction of apoptosis | 0.0021886 | 2.6164 |
| BP00148: Immunity and defense | 0.0022203 | 2.6538 |
| BP00207: Cell cycle control | 0.0030120 | 3.5843 |
Results from DAVID/Panther GO term analysis for the highly significant CpGs in each cell type and the mildly significant CpGs in T-cells.